1 Β· At a Glance
- Pregnancy or postpartum (puerperium) + suspected VTE β investigate urgently and involve obstetrics Β± haematology/medicine early.
- In clinically suspected DVT or PE, start therapeutic-dose LMWH immediately (weight-based, section 7) before imaging confirms the diagnosis β unless anticoagulation is strongly contraindicated. Do not wait for a scan.
- Suspected DVT β compression duplex ultrasound is the primary test (section 4).
- Suspected PE β ECG + CXR first; if DVT symptoms are present, ultrasound may confirm VTE and avoid chest imaging; otherwise V/Q scan or CTPA depending on the CXR and local availability (section 5).
- D-dimer has no role in diagnosing VTE in pregnancy β do not use it to exclude VTE here; this differs from standard non-pregnant pathways (section 6).
2 Β· Clinical Presentation β DVT
- Unilateral leg swelling β a circumference difference is more informative than swelling alone
- Leg pain, tenderness, or calf/thigh discomfort
- Lower abdominal, back or buttock pain can reflect extension into the iliac/pelvic veins β consider iliac vein thrombosis if the whole limb is swollen
- Pregnancy itself commonly causes bilateral leg swelling/oedema, especially in the third trimester β this overlaps with DVT symptoms; unilateral asymmetry is the key discriminator
- Low-grade pyrexia and a mild leucocytosis can occur with VTE and do not exclude it
2 Β· Clinical Presentation β PE
- Sudden or unexplained dyspnoea
- Pleuritic chest pain
- Tachycardia, hypoxia
- Haemoptysis
- Syncope, pre-syncope, or collapse
- Coexisting symptoms/signs of DVT
- Severe/unstable presentation: collapse, shock, severe hypoxaemia, cardiac arrest β treat as massive PE (section 9)
3 Β· Immediate Assessment
- ABCDE approach
- Maternal vital signs and oxygen saturation
- ECG
- IV access; bloods where indicated (FBC, coagulation screen, U&E, LFTs β see section 7, taken before anticoagulation if possible but do not delay treatment)
- Assess haemodynamic stability
- Consider fetal assessment according to gestational age and local obstetric practice
- Early senior/obstetric involvement when appropriate
- Haemodynamically UNSTABLE suspected PE (collapse, shock, severe hypoxaemia, cardiac arrest) β this is a medical emergency; go straight to section 9 (Massive/high-risk PE)
- Haemodynamically STABLE suspected PE β proceed via the stepwise diagnostic pathway in section 5
4 Β· Suspected DVT β Diagnosis
- Compression duplex ultrasound is the primary diagnostic test wherever DVT is clinically suspected
- Ultrasound positive β continue therapeutic LMWH; diagnosis confirmed
- Ultrasound negative + LOW clinical suspicion β anticoagulation can be discontinued
- Ultrasound negative + HIGH clinical suspicion β discontinue anticoagulant treatment but repeat the ultrasound on days 3 and 7; if repeat testing is negative, no further treatment is required; if repeat testing confirms DVT, recommence and continue anticoagulation
- Suspected iliac vein thrombosis (back/buttock pain, whole-limb swelling): consider Doppler ultrasound of the iliac vein, magnetic resonance venography, or conventional contrast venography
- Continue therapeutic LMWH throughout this diagnostic process unless treatment is strongly contraindicated
- Do NOT apply the standard non-pregnant DVT/Wells pathway automatically β D-dimer and pretest probability tools are not validated in pregnancy (section 6)
5 Β· Suspected PE β Diagnosis
- Initial investigations: ECG, chest X-ray (CXR), routine bloods (FBC, coagulation screen, U&E, LFTs), and assessment for DVT symptoms/signs
- If DVT symptoms/signs are present: perform compression duplex ultrasound. If it confirms DVT, no further investigation for PE is necessary β continue treatment for VTE
- If no DVT symptoms, or ultrasound is negative, chest imaging is needed: CXR normal β ventilation/perfusion (V/Q) scan (the ventilation component can often be omitted, reducing fetal radiation dose further); CXR abnormal with clinical suspicion of PE β CTPA is preferred over V/Q
- Radiation trade-off (discuss with the woman where feasible, and obtain informed consent before either test): CTPA gives a low fetal radiation dose but a comparatively higher maternal breast radiation dose (small increased lifetime breast cancer risk); V/Q gives a lower maternal breast dose but a slightly higher theoretical childhood cancer risk to the fetus β in both cases the absolute risk is very small
- Neither CTPA nor V/Q is universally preferred β the choice depends on CXR findings, clinical circumstances, local availability, and these radiation considerations
- If initial imaging is normal but clinical suspicion of PE remains: carry out alternative or repeat testing; continue anticoagulant treatment until PE is definitively excluded
6 Β· D-dimer in Pregnancy
- D-dimer testing should NOT be performed in the investigation of acute VTE in pregnancy, per current RCOG guidance.
- Reason: D-dimer rises progressively through normal pregnancy and is frequently 'abnormal' by term and postpartum even without VTE β a positive result is not diagnostic, and no validated pregnancy-specific cut-off exists.
- Pretest probability scoring tools (e.g. Wells) are also not currently validated for use in pregnancy β there is no evidence to support their use here.
- This is a genuine divergence from standard non-pregnant VTE pathways, but note NICE NG158 (which underpins the non-pregnant D-dimer/Wells pathway) explicitly excludes pregnancy from its scope in the first place β so there is no direct NICE-vs-RCOG conflict to reconcile, RCOG simply governs.
7 Β· Anticoagulation While Awaiting Diagnosis
- Start immediately: in any woman with clinically suspected DVT or PE, begin therapeutic-dose LMWH before the diagnosis is confirmed by objective testing, unless treatment is strongly contraindicated β continue until VTE is excluded
- LMWH is the preferred anticoagulant. Dose by booking or early-pregnancy weight β not current weight:
- Enoxaparin β <50kg: 40mg BD or 60mg OD Β· 50β69kg: 60mg BD or 90mg OD Β· 70β89kg: 80mg BD or 120mg OD Β· 90β109kg: 100mg BD or 150mg OD Β· 110β125kg: 120mg BD or 180mg OD Β· >125kg: discuss with haematology
- Dalteparin β <50kg: 5000iu BD or 10,000iu OD Β· 50β69kg: 6000iu BD or 12,000iu OD Β· 70β89kg: 8000iu BD or 16,000iu OD Β· 90β109kg: 10,000iu BD or 20,000iu OD Β· 110β125kg: 12,000iu BD or 24,000iu OD Β· >125kg: discuss with haematology
- Tinzaparin β 175 units/kg once daily at all weights, based on booking/early-pregnancy weight
- There is insufficient evidence to prefer once-daily over twice-daily dosing β follow your local guideline for which regimen to use
- Renal impairment: use lower doses if creatinine clearance is below 30 mL/min (enoxaparin/dalteparin) or below 20 mL/min (tinzaparin) β discuss with haematology
- Monitoring: routine peak anti-Xa monitoring is not required, except at extremes of body weight (<50kg or β₯90kg) or with other complicating factors (e.g. renal impairment, recurrent VTE) β target peak anti-Xa 0.5β1.2 u/mL, taken 3 hours post-injection. Routine platelet count monitoring is not needed on LMWH; if postoperative and on unfractionated heparin, check platelets every 2β3 days from days 4β14
- Baseline bloods before starting anticoagulation: full blood count, coagulation screen, urea & electrolytes, liver function tests. Thrombophilia screening is NOT recommended before treatment β pregnancy itself alters the results
- Do not use vitamin K antagonists (e.g. warfarin) antenatally β teratogenic and fetal bleeding risk. Avoid DOACs/NOACs in pregnancy β they cross the placenta and lack safety data
- Heparin allergy or HIT: consider fondaparinux, danaparoid, argatroban or r-hirudin under specialist/haematology advice β none of these are licensed for use in pregnancy
8 Β· Confirmed DVT β Management
- Continue therapeutic-dose LMWH (dosing above) for the remainder of the pregnancy and for at least 6 weeks postnatally, until at least 3 months of treatment has been given in total
- Elevate the leg and apply a graduated elastic compression stocking in the initial management to reduce oedema; encourage early mobilisation with compression β bed rest is not required or beneficial
- Consider a temporary inferior vena cava (IVC) filter, particularly peripartum, for iliac vein DVT or recurrent PE despite adequate anticoagulation
- Teach the woman to self-inject and arrange safe disposal of needles/syringes
- Postpartum considerations and follow-up: postnatal review at an obstetric medicine or joint obstetricβhaematology clinic where possible; monitor platelets/anti-Xa only if indicated (see section 7)
- Specialist involvement: obstetrics, and haematology or obstetric medicine for ongoing management
9 Β· Confirmed PE
- Stable PE: continue therapeutic LMWH as above (remainder of pregnancy + β₯6 weeks postnatally, β₯3 months total); risk-stratify for outpatient vs admission per local practice; graduated compression stockings if DVT coexists
- Massive / high-risk / unstable PE β collapse, shock, severe hypoxaemia, RV dysfunction on echo β is a medical emergency:
- Resuscitation: assessed immediately by a multidisciplinary team of experienced clinicians including the on-call consultant obstetrician, senior physicians, haematology and radiology. Standard ABC resuscitation; if cardiac arrest occurs, start CPR with manual left-lateral uterine displacement/tilt, and perform a perimortem caesarean section by 5 minutes if resuscitation is unsuccessful and the pregnancy is beyond 20 weeks
- Arrange an urgent portable echocardiogram or CTPA within 1 hour of presentation
- Anticoagulation: IV unfractionated heparin is the preferred initial treatment in massive PE with cardiovascular compromise β loading dose 80 units/kg IV, then a continuous infusion at 18 units/kg/hour, adjusted against the APTT ratio (target 1.5β2.5Γ control; check 4β6h after the loading dose, 6h after any dose change, then at least daily once in range) using your local nomogram
- Obstetric, critical care and cardiology/respiratory/haematology involvement throughout, per local massive-PE pathway
- Thrombolysis: an EXCEPTIONAL treatment reserved for life-threatening PE with haemodynamic compromise β not routine treatment, because anticoagulation alone will not relieve the obstruction. If thrombolysis is given, omit the heparin loading dose and start the infusion at 18 units/kg/hour afterward. Main risk is maternal and fetal bleeding
- If not suitable for thrombolysis, or moribund: urgent discussion with cardiothoracic surgery regarding thoracotomy/surgical embolectomy
- Management (heparin vs thrombolysis vs surgery) is individualised by the senior multidisciplinary team β this is not protocol-driven
10 Β· LMWH + Labour / Delivery / Neuraxial Anaesthesia
- Advise the woman: once in established labour, or if she thinks she is in labour, she should not inject any further LMWH
- Planned delivery (elective caesarean or induction of labour): stop therapeutic LMWH 24 hours before the planned delivery
- Neuraxial (spinal/epidural) anaesthesia: should not be performed until at least 24 hours after the last dose of therapeutic LMWH
- After a neuraxial block: do not give LMWH for at least 4 hours after spinal anaesthesia or after epidural catheter removal, and do not remove an epidural catheter within 12 hours of the most recent LMWH injection
- Labour starts unexpectedly shortly after an LMWH dose: bleeding complications are uncommon, but monitor closely and involve senior obstetric/anaesthetic input; if regional anaesthesia is being considered, coordinate timing with anaesthetics as above
- At term: if VTE occurs close to delivery, consider switching to IV unfractionated heparin, which is easier to manipulate and reverse β discontinue subcutaneous unfractionated heparin 12 hours, and IV unfractionated heparin 6 hours, before induction or regional anaesthesia
- Caesarean section on therapeutic LMWH: consider wound drains (abdominal and rectus sheath) and close the skin with interrupted sutures to allow drainage of any haematoma; coordinate the timing of postoperative thromboprophylactic and treatment-dose LMWH with obstetrics, anaesthesia and haematology
- High bleeding risk: use IV unfractionated heparin (short half-life, reversible with protamine sulfate) until the bleeding risk factors have resolved
- There is no single blanket interval that applies to every LMWH dose or regimen β always confirm timing against the specific dose given and your local anaesthetic protocol; coordinate every delivery plan with obstetrics and anaesthesia in advance
11 Β· Postpartum / Puerperium
- Continue therapeutic anticoagulation for the duration of the pregnancy AND for at least 6 weeks postnatally, to a total of at least 3 months of treatment; reassess the ongoing risk of thrombosis before stopping
- Choice of anticoagulant postpartum: continue LMWH, or switch to warfarin β discuss the need for regular blood test monitoring with warfarin, particularly in the first 10 days of treatment
- If starting warfarin: avoid until at least the 5th postnatal day (later if increased postpartum haemorrhage risk); overlap with heparin until the INR is >2.0 for at least 24 hours; dose using a haematology-agreed nomogram, with INR checked on day 2 of warfarin treatment
- Breastfeeding: neither LMWH, unfractionated heparin, nor warfarin is contraindicated
- Follow-up: postnatal review, ideally at an obstetric medicine or joint obstetricβhaematology clinic
- Recurrence risk / patient education: safety-net on symptoms of recurrent VTE and of post-thrombotic syndrome (chronic leg swelling, pain, skin changes); discuss thromboprophylaxis needs for any future pregnancy at follow-up
- This acute treatment pathway is separate from VTE prevention/thromboprophylaxis in women who have NOT had a VTE β see section 12
12 Β· Prevention of VTE in Pregnancy and Postpartum (Thromboprophylaxis)
- This section is prevention for at-risk women who have NOT had a confirmed VTE β do not confuse it with the treatment doses in sections 7β11, which apply once VTE is suspected or confirmed.
- Interim update β RCOG position statement, September 2026: RCOG has issued interim clinical guidance aligning Green-top Guideline 37a with the NHS England Maternal Care Bundle, pending a full revised edition of 37a expected Spring 2027. Follow current 37a with these amendments:
- All pregnant women are now screened for VTE risk at first contact with maternity care (from a positive pregnancy test), using a national self-assessment questionnaire
- BMI >50 kg/mΒ² is now, on its own, a trigger for thromboprophylaxis throughout pregnancy and for 6 weeks postpartum β previously this sat within a broader weighted risk score
- High-risk women (including a previous VTE, hyperemesis gravidarum with dehydration/immobility, or BMI >50) should be started on prophylactic-dose LMWH within 72 hours of risk identification, with follow-up in secondary care within 4 weeks to reassess risk
- Indicative Maternal Care Bundle prophylactic LMWH doses (once daily): enoxaparin 40mg (β₯100kg: 60mg); tinzaparin 3500 units (β₯100kg: 4500 units); dalteparin 5000 units (β₯100kg: 7500 units) β verify the exact current dose against the live RCOG/NHS England Maternal Care Bundle documents before using, as this is an evolving interim position, and note these are prevention doses, not treatment doses
- Other established risk factors from standing Green-top 37a remain relevant alongside the BMI-50 trigger: previous VTE, thrombophilia, obesity, age >35, parity β₯3, smoking, gross varicose veins, current systemic infection, immobility, pre-eclampsia, multiple pregnancy, IVF pregnancy, caesarean section (especially emergency), prolonged labour, mid-cavity/rotational operative delivery, and postpartum haemorrhage >1L or transfusion
- Duration follows the individual risk assessment β typically continued to delivery antenatally, and for 6 weeks postnatally for higher-risk indications (shorter courses apply to some lower-risk indications) β follow your local protocol based on current 37a
13 Β· Important Differential Diagnoses
- For suspected PE: pneumonia, pneumothorax, acute coronary syndrome, aortic pathology, peripartum cardiomyopathy, asthma, anaemia, sepsis, and β where clinically relevant β amniotic fluid embolism
- For suspected DVT: cellulitis, musculoskeletal pain, superficial thrombophlebitis, compression from the gravid uterus, a ruptured Baker's cyst, and other causes of unilateral leg swelling
14 Β· Red Flags β Immediate Senior / Obstetric / Critical Care Involvement
- Hypotension or shock
- Severe hypoxaemia
- Syncope or collapse
- Cardiac arrest
- Severe respiratory distress
- Evidence of right-heart strain or acute RV failure
- Massive PE
- Major bleeding, or a contraindication to anticoagulation in a woman who needs it
- Any other situation requiring urgent multidisciplinary management
15 Β· Quick ED Flowchart
Pregnant / postpartum patient with suspected VTE
β
Suspected DVT? β compression ultrasound pathway (section 4)
β
Suspected PE? β assess stability β ECG/CXR β DVT symptoms present? β appropriate imaging pathway (section 5)
β
Start/continue therapeutic LMWH when indicated, throughout work-up
β
Confirmed or excluded
β
Appropriate specialist management and follow-up (sections 8β12)